Kintor Pharmaceutical Limited Stock Performance
| KNTPF Stock | USD 0.22 0.04 15.38% |
The company secures a Beta (Market Risk) of 0.0956, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kintor Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kintor Pharmaceutical is expected to be smaller as well. At this point, Kintor Pharmaceutical has a negative expected return of -0.22%. Please make sure to verify Kintor Pharmaceutical's information ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Kintor Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kintor Pharmaceutical Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | 92 M |
Kintor |
Kintor Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 26.00 in Kintor Pharmaceutical Limited on September 29, 2025 and sell it today you would lose (4.00) from holding Kintor Pharmaceutical Limited or give up 15.38% of portfolio value over 90 days. Kintor Pharmaceutical Limited is currently producing negative expected returns and takes up 2.3352% volatility of returns over 90 trading days. Put another way, 20% of traded pink sheets are less volatile than Kintor, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kintor Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kintor Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Kintor Pharmaceutical Limited, and traders can use it to determine the average amount a Kintor Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0952
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KNTPF |
Based on monthly moving average Kintor Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kintor Pharmaceutical by adding Kintor Pharmaceutical to a well-diversified portfolio.
Kintor Pharmaceutical Fundamentals Growth
Kintor Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kintor Pharmaceutical, and Kintor Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kintor Pink Sheet performance.
| Return On Equity | -0.62 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (30.26) % | |||
| Current Valuation | 692.39 M | |||
| Shares Outstanding | 447.5 M | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 17.86 X | |||
| Revenue | 34.23 M | |||
| EBITDA | (833.82 M) | |||
| Cash And Equivalents | 387.49 M | |||
| Cash Per Share | 1.00 X | |||
| Total Debt | 147.5 M | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 3.06 X | |||
| Cash Flow From Operations | (1.05 B) | |||
| Earnings Per Share | (0.35) X | |||
| Total Asset | 2.07 B | |||
About Kintor Pharmaceutical Performance
By analyzing Kintor Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Kintor Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kintor Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kintor Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the Peoples Republic of China and internationally. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the Peoples Republic of China. Kintor Pharmaceutical operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 328 people.Things to note about Kintor Pharmaceutical performance evaluation
Checking the ongoing alerts about Kintor Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kintor Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kintor Pharmaceutical generated a negative expected return over the last 90 days | |
| Kintor Pharmaceutical has some characteristics of a very speculative penny stock | |
| Kintor Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 34.23 M. Net Loss for the year was (842.1 M) with profit before overhead, payroll, taxes, and interest of 34.23 M. | |
| Kintor Pharmaceutical Limited has accumulated about 387.49 M in cash with (1.05 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Kintor Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kintor Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Kintor Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kintor Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kintor Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kintor Pharmaceutical's pink sheet. These opinions can provide insight into Kintor Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kintor Pink Sheet analysis
When running Kintor Pharmaceutical's price analysis, check to measure Kintor Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kintor Pharmaceutical is operating at the current time. Most of Kintor Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Kintor Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kintor Pharmaceutical's price. Additionally, you may evaluate how the addition of Kintor Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |